MX388027B - Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos. - Google Patents
Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.Info
- Publication number
- MX388027B MX388027B MX2016006232A MX2016006232A MX388027B MX 388027 B MX388027 B MX 388027B MX 2016006232 A MX2016006232 A MX 2016006232A MX 2016006232 A MX2016006232 A MX 2016006232A MX 388027 B MX388027 B MX 388027B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- ligand
- necrosis factor
- specific antibodies
- tumour necrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
Abstract
La presente invención se refiere a anticuerpos o fragmentos de unión a antígeno del mismo, que se unen específicamente a TL1A; la invención además proporciona un método para obtener dichos anticuerpos y ácidos nucleicos que los codifican; la invención además se refiere a composiciones y métodos terapéuticos para usar estos anticuerpos para el tratamiento y/o la prevención de enfermedades, trastornos o afecciones mediados por TL1A.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361903836P | 2013-11-13 | 2013-11-13 | |
| US201361912374P | 2013-12-05 | 2013-12-05 | |
| PCT/US2014/065293 WO2015073580A1 (en) | 2013-11-13 | 2014-11-12 | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006232A MX2016006232A (es) | 2016-10-26 |
| MX388027B true MX388027B (es) | 2025-03-19 |
Family
ID=52434931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006232A MX388027B (es) | 2013-11-13 | 2014-11-12 | Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos. |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US9683998B2 (es) |
| EP (1) | EP3068801A1 (es) |
| JP (2) | JP6740126B2 (es) |
| KR (1) | KR102366076B1 (es) |
| CN (2) | CN105814081B (es) |
| AU (2) | AU2014348676B2 (es) |
| BR (1) | BR112016009797A2 (es) |
| CA (2) | CA2929784C (es) |
| IL (1) | IL245001B2 (es) |
| MX (1) | MX388027B (es) |
| MY (1) | MY182271A (es) |
| NZ (1) | NZ719092A (es) |
| PE (1) | PE20161092A1 (es) |
| PH (1) | PH12016500878B1 (es) |
| RU (1) | RU2708140C1 (es) |
| SA (1) | SA516371109B1 (es) |
| SG (2) | SG10201810298VA (es) |
| TW (1) | TWI736515B (es) |
| WO (1) | WO2015073580A1 (es) |
| ZA (1) | ZA201805277B (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| WO2013006810A1 (en) | 2011-07-06 | 2013-01-10 | Nestec Sa | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
| EP3495389A1 (en) | 2011-09-30 | 2019-06-12 | Teva Pharmaceuticals Australia Pty Ltd | Antibodies against tl1a and uses thereof |
| KR20240122922A (ko) | 2013-03-27 | 2024-08-13 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| CN105814081B (zh) | 2013-11-13 | 2021-02-02 | 辉瑞大药厂 | 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途 |
| RU2017122720A (ru) | 2014-12-05 | 2019-01-10 | Нестек С.А. | Непрямые однородные анализы по изменению подвижности для детекции биологических препаратов в образцах пациента |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| JP6788010B2 (ja) * | 2015-12-09 | 2020-11-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | インビボ相互作用様式を決定するための方法 |
| CR20180365A (es) * | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US10968279B2 (en) * | 2016-05-09 | 2021-04-06 | Bristol-Myers Squibb Company | TL1A antibodies and uses thereof |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| AU2017378393B2 (en) | 2016-12-14 | 2023-03-09 | Bt Bidco, Inc. | Treatment of a disease of the gastrointestinal tract with a TNF inhibitor |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP2020525445A (ja) * | 2017-06-21 | 2020-08-27 | セファロン・インコーポレイテッドCephalon,Incorporated | カチオン交換クロマトグラフィーの洗浄緩衝液 |
| CN119735681A (zh) | 2018-04-25 | 2025-04-01 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| EP3969621A4 (en) * | 2019-05-14 | 2023-01-25 | Prometheus Biosciences, Inc. | TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES |
| CN122060049A (zh) | 2019-09-13 | 2026-05-19 | 协和麒麟株式会社 | DcR3变体 |
| TW202600603A (zh) * | 2019-10-24 | 2026-01-01 | 美商普羅米修斯生物科學股份有限公司 | 針對類-tnf配體1a (tl1a)之人類化抗體及其用途 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| JP7227895B2 (ja) * | 2019-12-23 | 2023-02-22 | 株式会社堀場製作所 | 相互作用検出方法、相互作用検出装置及びバイオチップ再生キット |
| EP4171632A2 (en) * | 2020-06-26 | 2023-05-03 | Pfizer Inc. | Methods of treating inflammatory bowel disease with tl1a antibodies |
| CA3190012A1 (en) * | 2020-08-19 | 2022-02-24 | Adam ZWOLAK | Materials and methods of using engineered ligands |
| IL302791A (en) * | 2020-11-13 | 2023-07-01 | Prometheus Biosciences Inc | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
| KR20230158494A (ko) * | 2021-02-18 | 2023-11-20 | 프로메테우스 바이오사이언시즈, 인크. | 항-tl1a 항체 조성물 및 폐에서의 치료 방법 |
| GEAP202416596A (en) * | 2021-02-18 | 2024-10-28 | Cedars Sinai Medical Center | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| WO2023009545A1 (en) * | 2021-07-27 | 2023-02-02 | Prometheus Biosciences, Inc. | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| CN113759112B (zh) * | 2021-09-27 | 2022-05-24 | 北京美联泰科生物技术有限公司 | 一种脑特异性蛋白产物9.5的冻干方法 |
| US20240059799A1 (en) * | 2022-05-11 | 2024-02-22 | Pfizer Inc. | Anti-tl1a antibodies and methods of use thereof |
| CN119894931A (zh) | 2022-07-27 | 2025-04-25 | 赛福伦有限责任公司 | 用于治疗溃疡性结肠炎和克罗恩病的抗tl1a抗体 |
| AR130041A1 (es) * | 2022-07-27 | 2024-10-30 | Cephalon Llc | Formulaciones de anticuerpos anti-tl1a |
| IL325993A (en) | 2023-08-11 | 2026-03-01 | Paragon Therapeutics Inc | TL1A binding proteins and methods of use |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
| CN117659174B (zh) * | 2023-11-10 | 2026-07-31 | 广州珺柏诺医疗科技有限公司 | 一种识别eb病毒barf1蛋白的单克隆抗体1b6及其应用 |
| CN121851173A (zh) * | 2023-11-30 | 2026-04-14 | 北京智仁美博生物科技有限公司 | 抗肿瘤坏死因子样配体1a的抗体及其用途 |
| AU2024406222A1 (en) | 2023-12-20 | 2026-06-04 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
| TW202542181A (zh) * | 2023-12-26 | 2025-11-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 特異性結合類tnf配體1a(tl1a)之單株抗體或其抗原結合片段及其用途 |
| AU2025213136A1 (en) | 2024-01-24 | 2026-07-16 | Shattuck Labs, Inc. | Antibodies that bind tnfrsf25 |
| WO2025160331A1 (en) | 2024-01-26 | 2025-07-31 | Futuregen Biopharmaceutical (Beijing) Co., Ltd. | Antibodies capable of specifically binding tl1a and use thereof |
| CN120590530A (zh) | 2024-03-05 | 2025-09-05 | 帆礼生物技术(武汉)有限公司 | 靶向tl1a的抗体及其应用 |
| TW202613167A (zh) | 2024-05-17 | 2026-04-01 | 美商建南德克公司 | 使用抗tl1a抗體治療發炎性腸病之方法 |
| WO2025252194A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏先声药业有限公司 | 抗体-激素药物偶联物及其用途 |
| US20260062471A1 (en) * | 2024-08-28 | 2026-03-05 | Earendil Labs Inc. | Antibody and use thereof |
| WO2026056853A1 (zh) * | 2024-09-10 | 2026-03-19 | 先声药业有限公司 | Tl1a抗体及其应用 |
| WO2026060117A1 (en) * | 2024-09-13 | 2026-03-19 | Mirador Therapeutics, Inc. | Bispecific antibodies binding to tl1a and osmr |
| CN122381183A (zh) | 2025-01-13 | 2026-07-14 | 恒元生物医药科技(苏州)有限公司 | TL1A结合分子、IL-23p19结合分子和双特异性抗原结合分子及其用途 |
| WO2026158530A1 (zh) * | 2025-01-24 | 2026-07-30 | 信立泰(成都)生物技术有限公司 | 一种抗tl1a抗体或其抗原结合片段及用途 |
| CN120173113B (zh) * | 2025-03-11 | 2026-03-31 | 江苏荃信生物医药股份有限公司 | 抗人tl1a单克隆抗体及其相关试剂盒和检测方法 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM. |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| WO1995007994A2 (en) | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| HUT75162A (en) | 1993-11-16 | 1997-04-28 | Depotech Corp | Vesicles with controlled release of actives |
| US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
| DE69535669T2 (de) | 1994-05-09 | 2008-12-04 | Oxford Biomedica (Uk) Ltd. | Retrovirale vektoren mit verminderter rekombinationsrate |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US5985320A (en) | 1996-03-04 | 1999-11-16 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
| DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| WO1999018792A1 (en) | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| ES2198922T3 (es) | 1998-06-24 | 2004-02-01 | Advanced Inhalation Research, Inc. | Particulas porosas grandes emitadas por un inhalador. |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| MXPA02001264A (es) | 1999-08-04 | 2002-07-22 | Amgen Inc | Fhm, nuevo miembro de la familia de supergenes de ligando de factor de necrosis tumoral. |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| DK1575517T3 (da) | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| US20090317388A1 (en) | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| MX2010005282A (es) * | 2007-11-13 | 2010-08-31 | Teva Pharma | Anticuerpos humanizados contra tl1a. |
| PT3190128T (pt) | 2008-09-17 | 2019-02-07 | Xencor Inc | Composições e métodos para tratar distúrbios mediados pela ige |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| AU2012259312A1 (en) | 2011-05-20 | 2013-12-12 | Government Of The United States, As Represented By The Secretary Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
| JP5586783B2 (ja) * | 2011-05-31 | 2014-09-10 | Ykk株式会社 | 開離嵌挿具付きスライドファスナー及び射出成形用金型 |
| EP3495389A1 (en) * | 2011-09-30 | 2019-06-12 | Teva Pharmaceuticals Australia Pty Ltd | Antibodies against tl1a and uses thereof |
| CN105814081B (zh) * | 2013-11-13 | 2021-02-02 | 辉瑞大药厂 | 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途 |
-
2014
- 2014-11-12 CN CN201480062129.3A patent/CN105814081B/zh active Active
- 2014-11-12 CA CA2929784A patent/CA2929784C/en active Active
- 2014-11-12 NZ NZ719092A patent/NZ719092A/en unknown
- 2014-11-12 SG SG10201810298VA patent/SG10201810298VA/en unknown
- 2014-11-12 MX MX2016006232A patent/MX388027B/es unknown
- 2014-11-12 CN CN202110052446.9A patent/CN113150144A/zh active Pending
- 2014-11-12 EP EP14833301.6A patent/EP3068801A1/en active Pending
- 2014-11-12 SG SG11201602671WA patent/SG11201602671WA/en unknown
- 2014-11-12 RU RU2016116168A patent/RU2708140C1/ru active
- 2014-11-12 TW TW103139333A patent/TWI736515B/zh active
- 2014-11-12 AU AU2014348676A patent/AU2014348676B2/en active Active
- 2014-11-12 BR BR112016009797A patent/BR112016009797A2/pt not_active Application Discontinuation
- 2014-11-12 MY MYPI2016701698A patent/MY182271A/en unknown
- 2014-11-12 US US14/539,845 patent/US9683998B2/en active Active
- 2014-11-12 CA CA3056647A patent/CA3056647A1/en not_active Abandoned
- 2014-11-12 KR KR1020167015236A patent/KR102366076B1/ko active Active
- 2014-11-12 JP JP2016530124A patent/JP6740126B2/ja active Active
- 2014-11-12 PE PE2016000625A patent/PE20161092A1/es unknown
- 2014-11-12 IL IL245001A patent/IL245001B2/en unknown
- 2014-11-12 WO PCT/US2014/065293 patent/WO2015073580A1/en not_active Ceased
-
2016
- 2016-05-11 PH PH12016500878A patent/PH12016500878B1/en unknown
- 2016-05-12 SA SA516371109A patent/SA516371109B1/ar unknown
-
2017
- 2017-05-22 US US15/601,617 patent/US20180052175A1/en not_active Abandoned
-
2018
- 2018-08-10 ZA ZA2018/05277A patent/ZA201805277B/en unknown
-
2019
- 2019-05-24 US US16/422,256 patent/US11474112B2/en active Active
-
2020
- 2020-02-25 JP JP2020028964A patent/JP2020100635A/ja active Pending
- 2020-09-15 AU AU2020233652A patent/AU2020233652A1/en not_active Abandoned
-
2022
- 2022-07-28 US US17/815,802 patent/US12372536B2/en active Active
-
2025
- 2025-06-24 US US19/247,875 patent/US20260210971A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500878B1 (en) | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof | |
| CY1122415T1 (el) | Κυκλοπροπυλαμινες ως lsd1 αναστολεις | |
| CY1122314T1 (el) | Κυκλοπροπυλαμινες ως αναστολεις lsd1 | |
| IL287823A (en) | Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders | |
| UY38242A (es) | Anticuerpos anti-cd33, anticuerpos bioespecíficos anti- cd33/anti-cd3 y usos de éstos | |
| AR093394A1 (es) | Anticuerpos especificos del factor de crecimiento b derivado de plaquetas (pdgf-b), composiciones y usos de estos | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
| EA201691541A1 (ru) | Новые анти-baff антитела | |
| NZ719905A (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| EA201592143A1 (ru) | Новые бициклические ингибиторы бромодомена | |
| EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
| BR112017007012A2 (pt) | compostos anti-tnf | |
| EA201591746A1 (ru) | Способы и композиции для ингибирования бромодомен-содержащих белков | |
| PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
| EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
| EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
| EA201791768A1 (ru) | Иммуномодулирующие агенты | |
| EA201891539A1 (ru) | Соединения, ингибирующие металлоферменты | |
| EA201891446A1 (ru) | Молекулы полиспецифичных антител, имеющие специфичность к tnf-альфа, il-17a и il-17f | |
| EA201791249A1 (ru) | Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний | |
| EA201792282A1 (ru) | Способы лечения заболеваний | |
| MX2016001195A (es) | Metodos para mejorar sintomas de asma mediante el uso de benralizumab. | |
| MX2016012620A (es) | Anticuerpos contra atigeno de plaqueta 1a humano (hpa-1a). | |
| EA201891445A1 (ru) | Молекулы антител, которые связываются с tnf-альфа |